[294] Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP, Mayer EJ, Krauss RM. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993; 88:381-7.
[295] Grundy AM, Small LDL, atherogenic dyslipidaemia, and the metabolic syndrome. Circulation 1997; 95: 1-4.
[296] Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler A. High density lipoproteincholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
[297] Rönnemaa T, Laakso M, Kallio V, Pyörälä K, Marniemi J, Puukka P. Serum lipids, lipoproteins and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol 1989; 130: 632-45.
[298] Howard BV. Lipoprotein metabolism in diabetes. Curr Opin Lipidol 1994; 5: 216-20.
[299] Steinberg D, Parthasarathy S, Carew TE, Khou JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 913-24.
[300] Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-7.
[301] Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor-1 in treated type II diabetes and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes 1995; 44: 37-42.
[302] Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
[303] Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
[304] Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997; 20: 1767-71.
[305] Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effect of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J 1989; 10: 423-8.
[306] Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins C, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and left ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
[307] Ball SG, on behalf of the AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the acute infarction ramipril efficacy (AIRE) study. Lancet 1993; 342: 821-8.
[308] Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313-8.
[309] Smith DA. Comparative approaches to risk reduction of coronary heart disease in Tecumseh non-insulin-dependent diabetic population. Diabetes Care 1986; 9: 601-8.
[310] Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
[311] Smith JW, Marcus FE, Serokman R. Prognosis of patients with diabetes mellitus after myocardial infarction. Am J Cardiol 1984; 54: 718-21.
[312] Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 1993; 10: 449-54
[313] Löwel H, Dinkel R, Hörmann A, Stieber J, Görtler E. Herzinfarkt und Diabetes: Ergebnisse der Augsburger Herzinfarkt-Follow-up Studie 1985-1993. Diabetes Stoffw 1996; 5 (suppl 1): 19-23.
[314] Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischaemic heart disease associated with non insulin dependent diabetes mellitus in a defined population. Circulation 1990; 81: 899-906.
[315] Weiner DA, Ryan TJ, Parsons L, Fisher LD, Chaitman BR, Sheffield LT, Tristani FE. Significance of silent myocardial ischaemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1991; 68: 729-34.
[316] Airaksinen KEJ. Silent coronary artery disease in diabetes–a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001; 44: 259-66.
[317] Oswald GA, Corcoran S, Yudkin JS. Prevalence and risk of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984; i: 1264-7.
[318] Fava S, Aquilina O, Azzopardi J, Muscat HA, Fenech FF. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabet Med 1996; 13: 80-3.
[319] Lawson EB, Zinman B. The effect of intensive insulin therapy on macrovascular disease in type 1 diabetes: a systematic review and metaanalysis. Diabetes Care 1998; 21: 82-7.
[320] Singer DE, Nathan DM, Andersson KM, Wilson PWF, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-8.
[321] Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 1999; 99: 2626-32.
[322] Gray RP, Yudkin JS, Patterson DLH. Enzymatic evidence of impaired reperfusion in diabetic subjects after thrombolytic therapy for acute myocardial infarction—a role for plasminogen activator inhibitor ? Br Heart J 1993; 70: 530-6.
[323] Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-22.
[324] Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Forster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged ≥65 years: report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1994; 74: 334-9.
[325] Rahimtoola SH, Bennet AJ, Grunkemeier GL, Block P, Starr A. Survival at 15-18 years after coronary bypass grafting for angina in women. Circulation 1993; 88: 71-8.
[326] Carrozza JP, Kuntz RE, Fishman RF, Banin DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-9.
[327] Risum O, Abdelnoor M, Svennevig JL, Levorstad K, Gullestad L, Bjomerheim R, Simonson S, Nitter-Hange S. Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery. Scand J Thor Cardiovasc Surg 1996; 30: 71-5.
[328] BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997; 96: 1761-9.
[329] Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, Pichard AD, Kent KM, Satler LF, Wu H, Popma JJ, Leon MB. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9.